Pipeline

JIN-001

Target Disease Information

  • HSP90 (Heat Shock Protein 90) is a molecular chaperone that regulates protein folding, stability, and degradation within cells, playing a critical role in maintaining
    the stability of multiple oncoproteins essential for cancer cell growth and survival.
  • HSP90 inhibitors have been developed to block the function of these oncoproteins, thereby inhibiting cancer cell growth and survival.
    This highlights its therapeutic potential in various solid tumors.
  • Potential anticancer efficacy in ovarian cancer, lung cancer, glioblastoma, and other solid tumors.
  • Additionally, HSP90-targeted therapy is gaining attention for regulating compensatory pathways in cancer cells resistant to existing target therapies.

Introduction of JIN-001

  • Oral HSP90 inhibitor.
  • Targets dysregulated HSP90 expression in various cancers.
  • Demonstrates potent anticancer efficacy as monotherapy in ovarian cancer, lung cancer, and glioblastoma.
  • Combination therapy enhances sensitivity to existing anticancer drugs and delays resistance development.
  • Potential to expand indications to various solid tumors.

Mechanism of Action of JIN-001

  • Binds to the ATP-binding site of HSP90, inhibiting its function.
  • This destabilizes client proteins, leading to their degradation.
  • Client proteins include oncogenic signaling molecules such as EGFR, HER2, ALK, BCR-ABL, AKT, and c-MET.

Key Research Findings of JIN-001

  • Ovarian Cancer: Combination therapy of JIN-001 with cisplatin demonstrates superior tumor suppression compared to cisplatin alone, reducing the expression
    of key signaling and cisplatin resistance-related proteins, thereby prolonging the inhibition of cancer cell proliferation.
  • Lung Cancer
    • JIN-001 demonstrates tumor suppression without safety issues at tested doses when administered as monotherapy in lung cancer animal models and
      EGFR-TKI resistant lung cancer cell lines.
    • Combination of JIN-001 and EGFR-TKI in EGFR-TKI resistant lung cancer cell lines demonstrates tumor suppression without observable toxicity compared
      to monotherapy.
  • Glioblastoma
    • JIN-001 demonstrates blood-brain barrier (BBB) permeability, a major challenge in treating glioblastoma, in in vivo pharmacokinetic analysis.
    • JIN-001 demonstrates significant therapeutic efficacy in glioblastoma animal models, inhibiting tumor growth and survival via HSP90 regulation.
      This indicates its high potential as a treatment for central nervous system cancers.

JIN-001 Conference Presentation Status

Conference Topic
AACR 2025 (Poster presentation) Preclinical
ENA 2024 (Poster presentation) Preclinical
SNO 2024 (Poster presentation) Preclinical
SNO 2022 (Poster presentation) Preclinical
  • AACR: American Association for Cancer Research
  • ENA: EORTC-NCI-AACR
  • SNO: Society for Neuro-Oncology